Here are five things to know about the deal.
- AstraZeneca, based in London, will receive an upfront payment of $30 million and up to $120 million in future payments related to clinical, regulatory and sales-related milestones.
- AstraZeneca also maintains the option to negotiate a deal with Insmed to develop AZD7986 for the treatment of chronic obstructive pulmonary disease or asthma.
- AZD7986 was developed to inhibit an enzyme that plays a key role in inflammatory diseases.
- Insmed said it will conduct a mid-stage study of AZD7986 in non-cystic fibrosis bronchiectasis, which causes permanently dilated airways in the lungs due to chronic inflammation and infection, reported Reuters.
- The deal comes just two days after AstraZeneca sold the rights to an experimental anti-inflammatory drug to Parsippany-Troy Hills, N.J.-based Allergan for $250 million.
More articles on supply chain:
Coastal hospitals prepare supplies for Hurricane Matthew
Clinicians should take stock of patients, not shelves: 3 thoughts on supply chain’s role in patient care
J&J warns patients about cybersecurity vulnerabilities in insulin pump
At the Becker's 11th Annual IT + Revenue Cycle Conference: The Future of AI & Digital Health, taking place September 14–17 in Chicago, healthcare executives and digital leaders from across the country will come together to explore how AI, interoperability, cybersecurity, and revenue cycle innovation are transforming care delivery, strengthening financial performance, and driving the next era of digital health. Apply for complimentary registration now.
